The Journal of Gene Medicine,
Journal Year:
2023,
Volume and Issue:
26(1)
Published: Nov. 27, 2023
Abstract
Introduction
Endometrial
cancer
(EC)
is
a
prevalent
malignancy
affecting
the
female
population,
with
an
increasing
incidence
among
younger
age
groups.
DNA
methylation,
common
epigenetic
modification,
well‐established
to
play
key
role
in
progression.
We
suspected
whether
methylation
could
be
used
as
biomarkers
for
EC
prognosis.
Methods
In
present
study,
we
analyzed
bulk
RNA‐sequencing
data
from
544
patients
and
430
TCGA‐UCEC
cohort.
applied
weighted
correlation
network
analysis
select
gene
set
associated
panoptosis.
conducted
between
transcriptomic
of
selected
genes
identify
valuable
sites.
These
sites
were
further
screened
by
Cox
regression
least
absolute
shrinkage
selection
operator
analysis.
Immune
microenvironment
differences
high‐risk
low‐risk
groups
assessed
using
single‐sample
enrichment
analysi,
xCell
MCPcounter
algorithms.
Results
Our
results
identified
five
(cg03906681,
cg04549977,
cg06029846,
cg10043253
cg15658376)
significant
prognostic
value
EC.
constructed
model
these
sites,
demonstrating
satisfactory
predictive
performance.
The
group
showed
higher
immune
cell
infiltration.
Notably,
site
cg03906681
was
negatively
related
CD8
T
infiltration,
whereas
cg04549977
exhibited
positive
correlations
particularly
macrophages,
activated
B
cells,
dendritic
cells
myeloid‐derived
suppressor
cells.
PD0325901_1060
strongly
correlated
risk
scores,
indicating
potential
therapeutic
response
patients.
Conclusion
have
developed
robust
methylation‐based
EC,
which
holds
promise
improving
prognosis
prediction
personalized
treatment
approaches.
findings
may
contribute
better
management
patients,
identifying
those
at
who
benefit
tailored
interventions.
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
587, P. 216659 - 216659
Published: Feb. 15, 2024
Despite
the
challenges
posed
by
drug
resistance
and
side
effects,
chemotherapy
remains
a
pivotal
strategy
in
cancer
treatment.
A
key
issue
this
context
is
macroautophagy
(commonly
known
as
autophagy),
dysregulated
cell
death
mechanism
often
observed
during
chemotherapy.
Autophagy
plays
cytoprotective
role
maintaining
cellular
homeostasis
recycling
organelles,
emerging
evidence
points
to
its
significant
promoting
progression.
Cisplatin,
DNA-intercalating
agent
for
inducing
cycle
arrest,
encounters
treatments.
Recent
studies
have
shown
that
autophagy
can
contribute
cisplatin
or
insensitivity
tumor
cells
through
various
mechanisms.
This
be
mediated
protective
autophagy,
which
suppresses
apoptosis.
Additionally,
autophagy-related
changes
metastasis,
particularly
induction
of
Epithelial-Mesenchymal
Transition
(EMT),
also
lead
resistance.
Nevertheless,
pharmacological
strategies
targeting
regulation
apoptosis
offer
promising
avenues
enhance
sensitivity
therapy.
Notably,
numerous
non-coding
RNAs
been
identified
regulators
Thus,
therapeutic
associated
pathways
holds
potential
restoring
sensitivity,
highlighting
an
important
direction
future
clinical
research.
Molecules,
Journal Year:
2024,
Volume and Issue:
29(19), P. 4770 - 4770
Published: Oct. 9, 2024
Indole
derivatives
have
become
an
important
class
of
compounds
in
medicinal
chemistry,
recognized
for
their
wide-ranging
biological
activities
and
therapeutic
potential.
This
review
provides
a
comprehensive
overview
recent
advances
the
evaluation
indole-based
last
five
years,
highlighting
roles
cancer
treatment,
infectious
disease
management,
anti-inflammatory
therapies,
metabolic
disorder
interventions,
neurodegenerative
management.
shown
significant
efficacy
targeting
diverse
pathways,
making
them
valuable
scaffolds
designing
new
drugs.
Notably,
these
demonstrated
ability
to
combat
drug-resistant
cells
pathogens,
breakthrough
field,
offer
promising
options
chronic
diseases
such
as
diabetes
hypertension.
By
summarizing
key
findings
exploring
underlying
mechanisms,
this
underscores
potential
indole
addressing
major
healthcare
challenges,
thereby
instilling
hope
optimism
field
modern
medicine.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(1), P. 72 - 72
Published: Jan. 9, 2025
Ciprofloxacin,
a
widely
used
second-generation
fluoroquinolone
for
treating
bacterial
infections,
has
recently
shown
notable
anticancer
properties.
This
review
explores
progress
in
developing
ciprofloxacin
derivatives
with
properties,
emphasizing
key
structural
changes
that
improve
their
therapeutic
effectiveness
by
modifying
the
basic
group
at
position
7,
carboxylic
acid
3,
or
both.
It
further
investigates
mechanisms
which
these
fight
cancer,
such
as
inducing
apoptosis,
arresting
cell
cycle,
inhibiting
topoisomerase
I
and
II,
preventing
tubulin
polymerization,
suppressing
interleukin
6,
blocking
thymidine
phosphorylase,
multidrug
resistance
proteins,
hindering
angiogenesis.
Additionally,
it
outlines
future
directions,
enhancing
efficacy,
selectivity,
investigating
potential
synergy
other
chemotherapeutic
agents,
offering
promising
avenue
new
therapies
cancer.
Regenerative Therapy,
Journal Year:
2024,
Volume and Issue:
26, P. 14 - 26
Published: May 17, 2024
Kidney
stones
are
a
foremost
clinical
concern
in
urology
with
CaOx
crystals
accounting
for
roughly
80%
of
these
renal
formations.
This
research
endeavor
seeks
to
ascertain
the
protective
effects
Metformin-encapsulated
selenium
nanoparticles
(M@Se
NPs),
combined
55%
hydroethanolic
flower
extract
from
Myrtus
communis
L.
(MCL)
countering
formation
kidney
Male
Sprague
Dawley
rats.
The
particle's
diameter
was
measured
be
39
nm
and
13.8
DLS
HR-TEM
analysis.
Rat
groups
administered
MCL-M@Se
NPs
(1:1.5:1)
exhibited
reduced
stone
urine
serum
analysis
compared
negative
control
group.
Histological
evaluations
samples
using
H&E,
MTS
staining
indicated
subdued
presence
ECM
deposition
contrast
other
rat
groups.
Conclusively,
mechanism
against
damage
can
confidently
attributed
obstruction
MAPK
signaling
pathway.
RSC Advances,
Journal Year:
2024,
Volume and Issue:
14(50), P. 37114 - 37130
Published: Jan. 1, 2024
Drug
developers
are
currently
focusing
on
investigating
alternative
strategies,
such
as
“drug
repositioning”,
to
address
issues
associated
with
productivity,
regulatory
obstacles,
and
the
steadily
rising
cost
of
pharmaceuticals.
International Journal of Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
650, P. 123693 - 123693
Published: Dec. 9, 2023
Optimizing
a
sustained-release
drug
delivery
system
for
the
treatment
of
cystic
fibrosis
is
crucial
decreasing
dosing
frequency
and
improving
patients'
compliance
with
regimen.
In
current
work,
we
developed
an
injectable
PLGA
microparticle
formulation
loaded
ivacaftor,
CFTR
potentiator
that
increases
open
probability
anion
channel,
using
single
emulsion
solvent
evaporation
technique.
We
aimed
to
study
effect
different
parameters
on
characteristics
prepared
formulations
select
optimized
be
used
in
vivo
pharmacokinetic
mice.
First,
ivacaftor-loaded
microparticles
were
while
varying
their
formulations'
size,
morphology,
loading,
encapsulation
efficiency,
vitro
release
profiles.
All
showed
smooth
spherical
surfaces
internal
diameters
1.91–
6.93
µm,
loading
(DL)
3.91
–
10.3%,
percent
efficiencies
(%EE)
26.6
100%,
overall
slow
cumulative
profile.
selected
one
best
combined
%DL
%EE
values
(8.25,
90.7%,
respectively),
average
particle
size
6.83
bi-phasic
profile
(up
6
weeks)
its
pharmacokinetics
comparison
solubilized
ivacaftor
following
subcutaneous
(SC)
intravenous
(IV)
administration
mice,
respectively.
The
injected
steady
plasma
levels
over
period
28
days,
6-fold
increase
AUC
0
t
(71.6
µg/mL*h)
compared
intravenously
soluble
(12.3
µg/mL*h).
Our
results
suggest
this
novel
could
potentially
eliminate
need
frequent
daily
by
people
which
improve
ensure
successful
outcomes.
